Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.11 | N/A | -175.00% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.11 | N/A | -175.00% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed a cautious optimism about future developments. They are focused on their clinical programs and navigating current market conditions.
Management emphasized the importance of ongoing clinical trials.
They highlighted a commitment to advancing their pipeline despite current challenges.
This earnings report indicates that Soleno Therapeutics continues to face challenges, particularly with its earnings per share. Despite missing on EPS, the stock saw a slight increase of 1.01%, likely driven by investor optimism regarding the company's ongoing clinical trials and future potential. The lack of revenue data and guidance leaves some uncertainty for investors.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SIMON PPTY GROUP INC REIT
Nov 9, 2020